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ABSTRACT
Osteosarcoma is the main malignant primary bone tumor in children and 
adolescents for whom the prognosis remains poor, especially when metastases are 
present at diagnosis. Because we recently demonstrated that TGF-β/Smad cascade 
plays a crucial role in osteosarcoma metastatic progression, we investigated the 
effect of halofuginone, identified as an inhibitor of the TGF-β/Smad3 cascade, on 
osteosarcoma progression. A preclinical model of osteosarcoma was used to evaluate 
the impact of halofuginone on tumor growth, tumor microenvironment and metastasis 
development. In vivo experiments showed that halofuginone reduces primary tumor 
growth and lung metastases development. In vitro experiments demonstrated 
that halofuginone decreases cell viability mainly by its ability to induce caspase-3 
dependent cell apoptosis. Moreover, halofuginone inhibits the TGF-β/Smad3 cascade 
and the response of TGF-β key targets involved in the metastases dissemination 
process such as MMP-2. In addition, halofuginone treatment affects the "vicious cycle" 
established between tumor and bone cells, and therefore the tumor-associated bone 
osteolysis. Together, these results demonstrate that halofuginone decreased primary 
osteosarcoma development and associated lung metastases by targeting both the 
tumor cells and the tumor microenvironment. Using halofuginone may be a promising 
therapeutic strategy against tumor progression of osteosarcoma specifically against 
lung metastases dissemination.
INTRODUCTION
Osteosarcoma, the most common primary malignant 
bone tumor in children and adolescents (median age of 
diagnosis: 18 years) [1], represents the third highest 
cause of cancer-related death in this age group [2]. 
The survival rate that reaches approximately 50–70% 
at 5 years depending on the series have unfortunately 
remained unchanged during the last few decades [3]. The 
standard treatment of osteosarcoma consists of complete 
surgical resection associated with neoadjuvant and 
adjuvant chemotherapy composed of several agents such 
as doxorubicin, cisplatin, methotrexate or ifosfamide [4]. 
Radiotherapy is rarely used due to the radiation resistance 
of this type of tumor. Many patients die from metastatic 
diseases, lungs being the most common metastatic site for 
osteosarcoma [5]. The lack of response to conventional 
treatment in osteosarcoma patients and the poor prognosis 
for the metastatic forms of the pathology underscore the 
urgency to develop novel therapeutic strategies.
Alterations of bone remodeling associated with 
osteosarcoma development play a central role in the 
progression of this disease. Osteosarcoma is thus 
characterized by abnormal osteoid bone formation 
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and tumor-associated bone osteolysis which correlates 
with poor prognosis [6] and plays a crucial role in the 
establishment of a vicious cycle between the bone 
and cancer cells [7]. Briefly, the tumor cells secrete 
several factors able to induce, directly or indirectly the 
differentiation and maturation of osteoclasts leading 
to bone osteolysis [8, 9]. In turn, this osteoclastic bone 
destruction allows the release of growth factors stored in 
mineralized bone matrix which stimulate cancer cells and 
thus the tumor growth [7–9].
One of these factors stored in the bone matrix and 
released during the tumor-associated bone osteolysis 
is TGF-β1, a member of the TGF-β family. Although 
the role of TGF-β in cancer is complex, it is commonly 
accepted that during the later stages of disease, the 
TGF-β cascade promotes tumor progression mainly 
by its ability to stimulate epithelial to mesenchymal 
transition (in the context of carcinoma), tumor invasion, 
metastatic dissemination and/or escape from the immune 
system [10]. Concerning osteosarcoma, we recently 
demonstrated that TGF-β1 levels are higher in the serum 
of patients compared to healthy donors and that TGF-β/
Smad3 signaling pathway is activated in human biopsies. 
Second, we showed that blocking the TGF-β/Smad 
signaling pathway by overexpressing Smad7, a specific 
Smad inhibitor, slows down the growth of the primary 
tumor. This is mainly because Smad7 overexpression 
in tumor cells affects the "vicious cycle" established 
between tumor cells and bone cells by its ability to 
decrease osteoclast activity. Importantly, we showed 
that Smad7 overexpression in osteosarcoma cells or the 
treatment of mice with the TβRI inhibitor SD-208 inhibits 
the development of lung metastases demonstrating that 
the inhibition of TGF-β/Smad signaling pathway may 
represent a promising therapeutic strategy against tumor 
progression of osteosarcoma specifically against the 
development of lung metastases [11].
Halofuginone hydrobromide, 7-bromo-6-chloro-
3-[3-(3-hydroxy-2-piperidinyl)-2-oxopropyl]-4(3H)-
quinazolinone, is a derivative alkaloid from febrifugine 
isolated from a Chinese plant Dichroa febrifuga. 
Halofuginone was first identified as an inhibitor of type I 
collagen synthesis and is used as an anti-fibrotic drug [12]. 
In the context of cancer, halofuginone has recently showed 
its ability to reduce Kaposi sarcoma lesions in a completed 
phase II clinical trial in patients with AIDS-related Kaposi 
sarcoma [13]. In addition, by using different experimental 
models, halofuginone was shown to be effective against 
cancer progression for example, in the case of breast 
cancer [14], melanoma bone metastasis [15], myeloma 
[16], pancreas [17], Wilms tumor [18], hepatocellular 
carcinoma [19], bladder carcinoma [20], glioma [21] and 
prostate cancer [22].
Because the effects of halofuginone against cancer 
and fibrosis diseases are mainly associated with its ability 
to inhibit the TGF-β signaling pathway and because 
we demonstrated that blocking TGF-β is a promising 
therapeutic strategy against tumor progression of 
osteosarcoma, the aim of this work was to evaluate the 
effect of halofuginone on osteosarcoma progression and 
metastatic development.
RESULTS
Halofuginone inhibits in vivo tumor growth
To investigate the effect of halofuginone on 
osteosarcoma progression, we firstly used a mice 
preclinical experimental model of osteosarcoma induced 
by paratibial injection of HOS cells that mimics the 
human disease. As shown in Fig. 1A, the treatment of 
mice with halofuginone significantly inhibited the tumor 
growth in dose dependent manner. The mean tumor size 
at day 30 was 2524.3 ± 12.5 mm3, 2891.1 ± 54.5 mm3, 
1949.8 ± 154.5 mm3, 1336.6 ± 50.8 mm3 and 1329.1 ± 
70.1 mm3 when the mice were treated respectively with 
vehicle (control group) or with 0.2 μg/day, 0.5 μg/day, 
1 μg/day or 5 μg/day of halofuginone. In this context, 
immunohistochemical staining for the proliferative marker 
Ki67 in mice tumor samples showed that halofuginone 
treatment decreases tumor cell proliferation (Fig. 1B) 
during the first stage of tumor development (tumor sizes 
around 500 mm3). In addition, immunohistochemical 
staining for the apoptotic marker caspase-3 in the 
same samples showed that the treatment of mice with 
halofuginone increases tumor cell apoptosis (Fig. 1C).
Together, these results demonstrate that the 
treatment of mice with halofuginone reduces in vivo 
tumor growth and suggest that this effect is mainly due to 
a decrease of tumor cell proliferation associated with an 
increase of cell death.
Halofuginone induces in vitro cell death
To better understand the mechanisms involved 
in halofuginone-induced inhibition of osteosarcoma 
tumor growth, we next performed in vitro experiments. 
We firstly demonstrated that halofuginone significantly 
inhibits the viability of four osteosarcoma cell lines 
in a dose dependent manner after 24 h incubation 
(Fig. 2A). We secondly studied whether the reduced 
survival of osteosarcoma cells by halofuginone was 
associated with apoptosis induction. Flow cytometric 
annexin V/PI assay showed that halofuginone induces an 
early and late apoptotic cell populations in a dose-and 
time-dependent manner (Fig. 2B). The percentage of 
cells in early apoptosis (AnnexinV+/PI-) reached 0.62% 
in the absence of halofuginone and reached 3.05% and 
5.37% after respectively 12 h and 24 h of cell treatment 
with 100 nM halofuginone. Similarly, the percentage of 
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Figure 1: Halofuginone inhibits osteosarcoma primary tumor growth. A. Mice were injected with 2.106 HOS cells in each 
group. One day after cell injection, mice were daily intraperitoneal injected with 0.2 μg/mouse (n = 4), 0.5 μg/mouse (n = 4), 1 μg/mouse 
(n = 10) or 5 μg/mouse (n = 10) halofuginone or with vehicle (control group, n = 10). The results are representative of 2 independent 
experiments. The mean tumor volumes were calculated from day 1 to day 30. (Mean ± SEM; ***p < 0.005). B. Tumor samples (tumor 
sizes around 500 mm3) were fixed, embedded in paraffin, sectioned and stained with Ki-67. Representative photomicrographs per group 
are shown. C. Tumor samples (tumor sizes around 500 mm3) were fixed, embedded in paraffin, sectioned and stained with Caspase-3. 
Representative photomicrographs per group are shown.
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cells in late apoptosis (AnnexinV+/PI+) reached 0.69% 
in the absence of halofuginone and reached 1.08% and 
3.82% after respectively 12 h and 24 h of treatment with 
100 nM halofuginone. Thirdly, caspases-3/7 activity was 
measured in HOS and U2OS cells after 24 h incubation 
with halofuginone. As shown in Fig. 2C, halofuginone 
stimulated caspase-3/7 activity in a dose dependent 
manner. Finally, western immunoblotting analysis 
demonstrated the cleavage of caspase-3 and PARP in a 
dose dependent manner in HOS and U2OS cell lines 
(Fig. 2D).
Together, these results show that halofuginone 
inhibits cell viability in vitro and suggest that this effect 
is mainly due to a decrease of tumor cell proliferation 
possibly associated with an increase in cell death.
Halofuginone inhibits tumor associated 
bone osteolysis
Because osteosarcoma-associated alteration of bone 
remodeling plays a central role in the development and 
progression of primary bone tumors, we evaluated the 
ability of halofuginone to alter tumor-associated bone 
remodeling. To this aim, the bone microarchitecture was 
examined in mice bearing HOS tumors using a high-
resolution X-ray micro-CT system. First, to evaluate 
the ability of halofuginone to affect the production of 
bone, we specifically quantified ectopic bone formation. 
As shown in Fig. 3A, the ectopic bone volume in mice 
treated with 1 μg/day and 5 μg/day halofuginone was 
significantly higher than in mice injected with vehicle 
(1.99 ± 0.06 mm3 and 1.99 ± 0.08 mm3 vs. 0.81 ± 0.02 mm3 
respectively, p < 0.005). We then analyzed the ability of 
halofuginone to alter bone osteolysis by evaluating the 
specific trabecular bone volume (BV/TV), trabecular 
number (Tb.N) and trabecular thickness (Tb.Th) when 
the tumor sizes reached 1000 mm3. As shown in Fig. 3B, 
control mice had lower trabecular bone volume than mice 
treated with 1 μg/day and 5 μg/day (6.72 ± 0.43% vs. 
16.45 ± 0.68% and 12.37 ± 0.83%, p < 0.005 and p < 0.05 
respectively). Moreover, control mice had a significant 
lower Tb.Th than mice treated with for example 1 μg/day 
halofuginone (0.095 ± 0.004 mm vs. 0.120 ± 0.002 mm, 
p < 0.05). Similarly, the Tb.N was also lower in the control 
group compared to the 1 μg/day halofuginone treated 
group (0.75 ± 0.06 /mm vs. 1.35 ± 0.04 /mm; p < 0.005). 
Similar results are observed when tumor volumes reached 
around 500 mm3 (data not shown). Interestingly, systemic 
treatment of mice with halofuginone does not significantly 
affect bone volume in the absence of tumor (Fig. 3C). To 
understand the effect of halofuginone on bone osteolysis, 
we next analyzed the expression of two osteolytic 
genes, RANKL and IL-11, in tumor biopsies from mice. 
qRT-PCR analysis indicated that bone tumors from 
mice treated with 1 μg/day and 5 μg/day halofuginone 
expressed significantly lower mRNA levels of RANKL 
and IL-11 than control groups (Fig. 3D, upper panel). 
Finally, halofuginone treatment inhibits the degradation 
of collagen evaluated by the measure of pyridinoline 
excretion in mice serum (Fig. 3D, lower panel) both 
when tumor volumes reached 1000 mm3 (left panel) and 
2500 mm3 (right panel).
Together these results demonstrate that halofuginone 
both decreased tumor-induced bone osteolysis and 
promoted tumor-induced bone formation, and suggest that 
these effects are partly due to the ability of halofuginone 
to reduce the expression of RANKL and IL-11 by 
tumors cells.
Treatment of mice with halofuginone inhibits the 
dissemination of pulmonary metastases
To evaluate the effect of halofuginone on 
pulmonary metastases development, the lungs of mice 
were removed when primary bone tumor volumes 
reached 2500 mm3. As shown in Figure 4, halofuginone 
reduced the incidence of lung metastases. In the absence 
of halofuginone treatment, 10 mice out of 10 (100%) 
developed lung metastases. By contrast, only 3 of 4 (75%) 
mice treated with 0.2 μg/day halofuginone, 2 of 
4 (50%) mice treated with 0.5 μg/day halofuginone 
and 4 out of 10 (40%) mice treated with 1 μg/day or 
5 μg/day halofuginone developed lung metastases 
(Fig. 4A). As shown in Fig. 4B, the treatment of mice 
with respectively 0.2 μg/day, 0.5 μg/day, 1 μg/day and 
5 μg/day halofuginone also diminished the number of 
lung metastases when lungs are infected. No mice in 
the 5 μg/day and 1 μg/day halofuginone treated groups 
developed more than 5 lung metastases. By contrast, 8 
mice in the control group developed more than 5 lung 
metastases.
Together, these results prove that halofuginone 
reduces both the incidence and the number of lung 
metastases.
Halofuginone blocks the TGF-β/Smad3 signaling 
pathway in osteosarcoma cells
Because halofuginone is known to reduce TGF-β 
signaling pathway in normal cells such as fibroblast 
[23] and in cancer cells such as melanoma [15] and 
promyelocytic leukemia [24], and because we recently 
demonstrated that TGF-β signaling plays a crucial role 
in the development of lung metastases in osteosarcoma, 
we then evaluated the effect of halofuginone on TGF-β 
signaling pathway in osteosarcoma cells. Firstly, we 
demonstrated that the incubation of HOS and/or U2OS 
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Figure 2: Halofuginone induces osteosarcoma cell death in vitro. A. Four osteosarcoma cell lines were treated for 24 hours with 
halofuginone as indicated. After incubation, cell viability was evaluated by WST-1 test. For each cell line, graph indicates the percentage 
of cell viability compared to untreated cells. Mean ± S.D. of two independent experiments, each performed in sixplicate is presented. 
B. Representative dot plots of untreated HOS cells and HOS cells treated with 100 nM halofuginone for 12 and 24 hours are shown 
(Representative graphs of two experiments). C. HOS and U2OS cells were treated with halofuginone as indicated for 24 hours. Relative 
caspase-3/7 activity was evaluated. Bars indicate the caspase-3/7 activity for each halofuginone concentration tested (mean ± S.D.) of at 
least two independent experiments, each performed in triplicate (***p < 0.005, **p < 0.01). D. HOS cells (left panels) and U2OS cells 
(right panels) were treated with halofuginone as indicated for 24 hours. After incubation, Caspase-3 and PARP levels were detected by 
Western Blot analysis of whole cell lysates. Actin antibody was used as internal control. Representative blots of three experiments were 
shown.
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Figure 3: Halofuginone affects tumor associated bone remodeling. Paratibial injections of 2.106 HOS tumor cells were 
performed in 3 groups of nude mice (vehicle, halofuginone 1 μg/mouse/day and 5 μg/mouse/day). Bone remodeling parameters were 
analysed on the tibia bearing tumor (A–B). A. Histogram represents the ectopic bone volume (mean ± S.E.M.) when the tumor volume 
reached 2500 mm3 in each group of 10 mice (treated with 1 μg/day/mouse or 5 μg/day/mouse halofuginone or vehicle) (***p < 0.005). 
B. Left panel : histogram represents the specific trabecular bone volume (mean ± S.E.M.) when the tumor volume reached 1000 mm3 in 
each group of 6 mice (treated with 1 μg/day/mouse or 5 μg/day/mouse halofuginone or vehicle) (***p < 0.005, *p < 0.05). Middle panel 
: Bars indicate the trabecular thickness (mean ± S.E.M.) in each group (*p < 0.05). Right panel : Bars indicate the trabecular number 
(mean ± S.E.M.) in each group (***p < 0.005, *p < 0.05). C. Left panel : Bone volumes of healthy controlateral legs were measured when 
the tumor volume reached 2500 mm3 (left panel). Histograms represent the mean ± S.E.M. in each group. Right panel : Bone volumes of 
healthy contralateral legs were measured 35 days after HOS cell injection. Histograms represent the mean ± S.E.M. in each group. D. Upper 
panels : RNA was extracted from tumor biopsies of mice treated with 1 μg/mouse/day, or 5 μg/mouse/day halofuginone or vehicle. RANKL 
(left panel) and IL-11 (right panel) mRNA steady-state levels were determined by quantitative RT-PCR. Bars indicate means ± S.D. Lower 
panels : Concentrations of pyridinoline in mice serum of control, 1 μg/mouse/day and 5 μg/mouse/day halofuginone groups were measured 
using the MicroVue Serum PYD EIA kit both when tumor volume reached 1000 mm3 (left panel) and 2500 mm3(right panel). Bars indicate 
means ± S.E.M performed in duplicate (*p < 0.05).
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cells with halofuginone during 10 h do not affect cell 
viability (Fig. 5A). In this context, to specifically evaluate 
the effect of halofuginone on TGF-β signaling, we chose 
to treat the cells only during 10 h, ie under experimental 
conditions which do not affect osteosarcoma cell viability. 
Halofuginone inhibits the ability of TGF-β to induce the 
phosphorylation of Smad3 (Fig. 5B), to transactivate 
the Smad3/4-specific reporter construct (CAGA)9-luc 
(Fig. 5C, left panel), and to stimulate the expression of 
CTGF (Fig. 5C, right panel), a specific TGF-β signaling 
pathway target gene, in HOS cells. Similar results were 
obtained with the U2OS cell line (Supplementary Fig. S1). 
To better understand by which mechanism halofuginone 
inhibits TGF-β signaling pathway, we investigated 
the effect of halofuginone on Smad7, TβRI and TβRII 
expressions. As indicated in Fig. 5D, halofuginone both 
induces Smad7 expression, and inhibits TβRI and TβRII 
expressions even at very low doses (5 nM).
Together, these results demonstrate that 
halofuginone inhibits TGF-β signaling pathway probably 
by its ability to increase Smad7 expression and to reduce 
the expression of the TGF-β receptors, TβRI and TβRII.
Halofuginone inhibits TGF-β key targets 
involved in the metastatic process
Since halofuginone is able to inhibit the TGF-β 
cascade in osteosarcoma cells, we evaluated the ability 
of halofuginone to inhibit TGF-β key targets involved in 
the metastatic process. As shown in Fig. 6A, zymography 
assay demonstrated that halofuginone strongly reduces 
the activation of MMP-2 in osteosarcoma cells, a 
metalloproteinase that plays a crucial role in the cell 
invasion process. Moreover, as shown in Fig. 6B, RT-
qPCR analysis indicated that halofuginone inhibits the 
ability of TGF-β to induce MMP-2 expression. In addition, 
RT-qPCR analysis from mice biopsies indicated that the 
expression by tumor cells of CXCR4 and ANGPTL4, two 
TGF-β target genes identified as key players to prime 
cancer cells towards the lungs, were both reduced when 
mice were treated with halofuginone (Fig. 6C). Finally, 
immunohistochemical staining for the endothelial marker 
CD146 in mice tumor samples showed that halofuginone 
treatment significantly decreased the angiogenic process 
compared to the untreated group by decreasing the number 
of vessels and their average size (Fig. 6D).
Together, these results prove that halofuginone 
inhibits TGF-β key targets involved in the metastatic 
process of osteosarcoma.
DISCUSSION
Currently a variety of agents appear to be of 
potential clinical interest for osteosarcoma, with an 
emphasis on molecular targeted approaches of signaling 
pathways [25–28]. Basic research thus identified specific 
targets and developed adapted strategies for osteosarcoma 
tumor inhibition. However, many of these therapeutic 
strategies focus on a single aspect of osteosarcoma 
tumor development and target only one point of the 
‘vicious circle’ between the tumor cells and bone 
cells, either the tumor cells or the tumor environment. 
A B
**
**
Figure 4: Treatment of mice with halofuginone inhibits lung metastases development. Mice were injected with HOS cells 
and treated with vehicle or halofuginone as indicated. Mice were sacrificed when tumor sizes reached 2500 mm3 and lungs were removed. 
A. Histogram indicates lung metastases incidence in each group. B. Graph indicates individual (dots) and mean (lines) numbers of lung 
metastases counted in mice lungs from each group (**p < 0.01).
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Figure 5: Halofuginone blocks the TGF-β/Smad3 cascade in osteosarcoma cells. A. HOS (left panel) and U2OS (right panel) 
cells were treated with halofuginone as indicated for 10 hours. After incubation, cell viability was evaluated by WST-1 test. For each 
cell line, histogram indicates the percentage of cell viability compared to untreated cells (Mean ± S.D. of two independent experiments, 
each performed in sixplicate; *p < 0.05). B. HOS cells were treated for 4 hours with halofuginone and then for 30 min in the presence 
or absence of TGF-β (5 ng/ml). Phospho-Smad3 levels were detected by Western Blot analysis of HOS whole cell lysates (upper panel). 
The specificity of the modulation was confirmed with an anti-Smad3 antibody (lower panel). C. Left panel : HOS cells were transfected 
with the Smad3/4-specific construct (CAGA)9-luc. 24 h after transfection, cells were treated with halofuginone for 4 hours and then for 
6 hours in the presence or absence of TGF-β (5 ng/ml). Bars indicate mean ± S.D. of at least two independent experiments carried out in 
triplicate (***p < 0.005, **p < 0.01, *p < 0.05). Right panel : HOS cells were treated with halofuginone for 4 hours and then for 6 hours 
in the presence or absence of TGF-β (5 ng/ml). After incubations, mRNA steady-state levels of the specific TGF-β target genes CTGF was 
determined by quantitative RT-PCR. Bars indicate means ± S.D. of at least two independent experiments, each performed in triplicate. 
D. HOS cells were treated or not with halofuginone during 10 hours as indicated. After incubations, mRNA steady-state levels of Smad7 
(left panel), TβRI (middle panel) and TβRII (right panel) were determined by quantitative RT-PCR. Bars indicate means ± S.D. of at least 
two independent experiments, each performed in triplicate.
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Figure 6: Halofuginone inhibits metastatic process. A. Zymography analysis of conditioned media from 10 h serum-free 
cultures of HOS (upper panel) and U2OS (lower panel) cells treated with halofuginone for 4 hours and then for 6 h in the presence or 
absence of 5 ng/mL TGF-β. A Coomassie blue stained gel representative of three independent experiments is shown. B. HOS (left panel) 
and U2OS (right panel) cells were treated with halofuginone for 4 hours and then for 6 hours in the presence or absence of TGF-β1  
(5 ng/ml). After incubation, MMP-2 mRNA steady-state levels were determined by quantitative RT-PCR. Bars indicate mean ± S.D. of at 
least two independent experiments carried out in triplicate. C. RNA was extracted from tumor biopsies of mice treated with 1 μg/mouse/day, 
5 μg/mouse/day halofuginone or vehicle. CXCR4 (left panel) and ANGPTL4 (right panel) mRNA steady-state levels were determined by 
quantitative RT-PCR. Bars indicate means ± S.D. D. Tumor samples (tumor sizes at 500 mm3) from mice treated or not with halofuginone 
as indicated were fixed, embedded in paraffin, sectioned and stained with CD146. Representative photomicrographs per group for HOS 
osteosarcoma mice are shown. Histograms represent the percentage of positive area for CD146 (left panel), the number of vessels per total 
area (in pixel) (middle panel) and the average size of vessels (right panel) in each group of mice (Mean ± SEM; *p < 0.05).
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These strategies have thus attempted to either induce 
apoptosis and/or cell cycle arrest of tumor cells or to 
target the tumor microenvironment by the inhibition of 
osteoclast-mediated bone destruction for example. During 
the last decade, new strategies have associated the use 
of chemotherapeutic drugs that target tumor cells and 
drugs that target osteoclasts allowing a better response 
to treatment. Future directions and challenges could be 
the discovery of drugs able to target several key points of 
the ‘vicious circle’ established between tumor cells and 
bone cells in order to limit treatment escape.
In this study, we demonstrated that halofuginone 
inhibits tumor growth in human osteosarcoma xenograft 
model in vivo. To understand whether the tumor growth 
inhibition observed in vivo was due to the inhibition 
of osteosarcoma cell proliferation, to the induction of 
tumor cell apoptosis and/or to the drug effect on cell 
microenvironment, we have first tested the direct potential 
effect of halofuginone on osteosarcoma cell viability using 
WST-1 assay. As previously described in other tumor cell 
lines such as multiple myeloma or melanoma cell lines 
[15, 16], we demonstrated that all the four osteosarcoma 
cell lines tested are sensitive to halofuginone. In addition, 
annexin V/PI double staining showed that halofuginone 
induced apoptosis in a dose- and time- dependent manner. 
How halofuginone modulates intracellular signaling 
cascade leading to apoptosis is not fully understood. 
Signaling pathways that are able to induce apoptosis 
have been schematically classified into i) extrinsic 
pathways initiated by death receptors and ii) intrinsic 
pathways initiated by mitochondrial events [29]. Here, 
we demonstrated that halofuginone induced the cleavage 
and activation of caspase-3 a common mediator of both 
apoptotic pathways. In addition, we demonstrated that 
halofuginone induced the cleavage of PARP, a substrate 
of caspase-3 known as an indicator of DNA damage and 
apoptosis. Whatever the exact involvement of the intrinsic 
and/or extrinsic pathways, we clearly demonstrated that 
halofuginone induces in vitro and in vivo osteosarcoma 
cell death and thus inhibits the in vivo tumor growth.
We next focused our attention on the effects of 
halofuginone on tumor cell microenvironment, specifically 
on bone remodeling. In this study, using microCT analysis, 
we demonstrated that halofuginone inhibits the tumor-
associated bone destruction by both promoting ectopic 
bone formation and preventing trabecular bone osteolysis. 
As first hypothesis, our results suggest that halofuginone 
effects on bone remodeling could be explained indirectly 
by the death of tumor cells induced by halofuginone. 
Since some studies showed that tumor cells produce 
osteoclast-activating factors which induce osteoclast 
precursor differentiation and activation [30, 31], the 
consequence of the decrease of the tumor cell number 
may be a diminution of the production and the release 
of osteolytic factors produced by tumor cells thus 
contributing to decreased osteoclast activity. As second 
hypothesis, our results suggest that halofuginone 
may act on bone remodeling by its ability to block the 
TGF-β signaling pathway. As previously described 
in many cancer cells such as melanoma [15], we here 
demonstrated that halofuginone inhibits TGF-β/Smad3 
signaling pathway by increasing Smad7 expression and/
or reducing TβRI and TβRII expressions. In this context, 
we demonstrated in tumor biopsies that halofuginone 
inhibits the expression of RANKL and IL-11 mRNA, two 
TGF-β target-cytokines that play a central role in bone 
osteolysis [30–32]. In addition, we recently demonstrated 
that blocking TGF-β signaling by overexpression of 
Smad7 in osteosarcoma cells inhibits the expression and 
release of osteolytic factors such as RANKL and IL-11 by 
tumor cells [11]. Finally, although the systemic treatment 
of mice with halofuginone did not show significant results 
on bone remodeling in the absence of tumor, we cannot 
rule out that halofuginone acts directly on osteoblast and 
or osteoclast activity. Here, we clearly demonstrated that 
halofuginone inhibits bone osteolysis associated to the 
tumor growth, which represents the first step of tumor 
development.
Finally, we have demonstrated that halofuginone 
inhibits the development of lung metastases. We recently 
showed that TGF-β signaling pathway plays a key role in 
the establishment and progression of osteosarcoma lung 
metastases. Indeed, overexpression of the Smad inhibitor 
Smad7, or the systemic injection of SD208, an inhibitor 
of TβRI kinase, inhibits the TGF-β signaling cascade 
and thus reduces the expression of TGF-β-regulated 
metastatic genes and the ability of TGF-β to stimulate 
migration and invasion of osteosarcoma cells [11]. 
Here, we demonstrated that the ability of halofuginone 
to inhibit the TGF-β/Smad3 cascade in osteosarcoma 
reduces the expression and activity of MMP-2, a protein 
highly implicated in the migration and invasion processes 
[11, 33, 34]. Interestingly, halofuginone was also able to 
inhibit the ability of TGF-β to stimulate ANGPTL4 and 
CXCR4 expression, two factors identified as key players 
to prime cancer cells for metastasis respectively towards 
the lungs [35] and towards the bones or the lungs [36]. 
Another major step in the metastatic process is the ability 
of TGF-β to stimulate tumor associated angiogenesis and 
thus the dissemination of tumor cells into the bloodstream 
[10]. In this context, we clearly demonstrated that 
halofuginone reduces the angiogenic process as shown 
by decreased immunohistochemical staining for the 
endothelial marker CD146, as previously reported with 
the inhibitor SD-208 [11].
To sum up, our data demonstrated that halofuginone 
decreased primary osteosarcoma development and 
associated lung metastases by targeting both the 
tumor cells and the bone remodeling. In this context, 
halofuginone represents a promising therapeutic drug 
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that can act at different key points of osteosarcoma 
progression: on tumor cells by inducing their apoptosis, on 
tumor microenvironment by inhibiting tumor associated 
osteolysis and on the metastatic process mainly by 
inhibiting the TGF-β signaling pathway.
MATERIALS AND METHODS
Cell culture and reagents
The human osteosarcoma cell lines MNNG/
HOS (HOS, young female high-grade osteosarcoma 
from femur origin transformed in vitro by N-methyl-
N’-nitro-N-nitrosoguanidine treatment), KHOS 
(derived from HOS by transformation using Kirsten 
murine sarcoma virus Ki-MSV), U2OS (young female 
osteosarcoma from tibia origin) and G292 (young female 
osteosarcoma) were purchased from the American Type 
Culture Collection (respectively CRL-1547™, CRL-
1544™, HTB-96™, CRL-1423™) and cultured in DMEM 
(Dulbecco’s Modified Eagle’s Medium, Lonza, Basel, 
Switzerland) supplemented with 10% fetal bovine serum 
(HyclonePerbio, Bezons, France) in a humidified 5% 
CO2/air atmosphere at 37°C. All cell lines were passaged 
for less than 3 months and were authenticated by short 
tandem repeat (STR) profiling. TGF-β1 and halofuginone 
(halofuginone hydrobromide, vetranal™) were respectively 
from R&D System, Inc (Minneapolis, MN) and Sigma 
(St Quentin-Fallavier, France). Halofuginone has been 
diluted in DPBS (Dulbecco’s Phosphate Buffer Saline, 
Biowhittaker).
Osteosarcoma mouse model
Four-week-old female Rj:NMRI-nude mice 
(Elevages Janvier, Le Genest Saint Isle, France) were 
maintained under pathogen-free conditions at the 
Experimental Therapy Unit (Faculty of Medicine, 
Nantes, France) in accordance with the institutional 
guidelines of the French Ethical Committee (CEEA 
Pays de la Loire n°06; project authorization n°1281.01) 
and under the supervision of authorized investigators. 
The mice were anesthetized by inhalation of a 
combination of isoflurane/air (1.5%, 1 L/min) before 
receiving an intramuscular injection of 2.106 HOS 
osteosarcoma cells in close proximity to the tibia, 
leading to a rapidly growing tumor in soft tissue with 
secondary contiguous bone invasion. One day after HOS 
cells injection,some mice received different doses either 
0.2 μg/mouse/ day (10 μg/kg/day), 0.5 μg/mouse/day 
(25 μg/kg/day), 1 μg/mouse/day (50 μg/kg/day), 
5 μg/mouse/day (250 μg/kg/day) of halofuginone or 
control vehicle (DPBS) by daily intraperitoneal injection. 
Note that the weight of each mouse was similar for 
each group at the beginning of the experiment and no 
weight loss was observed following treatment with 
halofuginone. The tumor volume (V) was calculated 
from the measurement of two perpendicular diameters 
using a caliper, according to the following formula: 
V = 0.5 × L × (S)2 as previously described [37]. Mice were 
sacrificed when the tumor volume reached 2500 mm3 for 
ethical considerations. Under these conditions, pulmonary 
metastases developed when primary tumor volumes were 
at least 2000 mm3.
Histologic analysis and immunohistochemistry of 
mice tumor samples
Tumor tissues were embedded in paraffin and 3-μm 
sections were cut and stained for caspase-3, Ki-67 and 
CD146 using respectively rabbit polyclonal anti-caspase-3 
(Cell Signaling), anti-Ki67 (Dako), anti-CD146 (Abcam) 
antibodies. Immunodetection was performed using DAB 
Substrate-Chromogen (Dako) and counterstained with 
hematoxylin. Quantification of relative caspase-3 positive 
surface, Ki-67 positive cells and CD146 immunostaining 
in tumor tissue were evaluated by ImageJ (NIH, Bethesda, 
MD) softwares.
Proliferation assay
Osteosarcoma cell lines were plated in DMEM with 
10% FBS and treated with halofuginone as indicated. Cell 
growth and viability were determined by using a WST-1 
cell proliferation assay kit (Takara bio inc.). Absorbance 
of the samples was measured at 440 nm wave length with 
Victor2™ (Perkin Elmer, life sciences) ELISA reader after 
2 hours incubation.
Cell cycle analysis
Osteosarcoma cell lines were incubated in the 
absence or the presence of halofuginone for 24 h, 
trypsinized, washed twice and incubated in PBS 
containing 0.12% Triton X-100, 0.12 mM EDTA and 
100 μg/mL ribonuclease A; 50 μg/mL propidium iodide 
was then added to each sample for 20 min at 4°C. Cell 
cycle distribution was analysed by flow cytometry 
(Cytomics FC500; Beckman Coulter, Roissy, France) 
based on 2N and 4N DNA content.
Annexine-V assay
Osteosarcoma cells were cultured and treated 
with or without halofuginone for 12 h or 24 h. Cells 
were washed and resuspended in 1X binding buffer 
(BD pharmingen™, BD Biosciences). Cells undergoing 
apoptosis were identified by flow cytometry (Cytomics 
FC500; Beckman Coulter, Roissy, France) after 20 min 
incubation with annexin V-FITC and propidium iodide.
Oncotarget14424www.impactjournals.com/oncotarget
Caspase 3/7 activity
Caspase 3/7 activity was measured using a 
Caspase-Glo assay kit (Promega). Briefly, cells were 
lysed in RIPA buffer (10 mM Tris pH8, 1 mM EDTA, 
150 mM NaCl, 1% NP40, 0.1% SDS) containing 
a cocktail of protease and phosphatase inhibitors 
(1 mM sodium orthovanadate (Na2VO4), 1 mM 
phenylmethylsulforyl fluoride (PMSF), 10 mM 
sodium fluoride (NaF), 10 mM N-ethylmaleimide 
(NEM), 2 μg/ml leupeptin and 1 μg/ml pepstatine) at 4°C 
and protein concentration was determined by BCA kit 
(Sigma, St Quentin-Fallavier, France). An equal volume 
of reagents was added to a white-walled 96-well plate 
containing equal amounts of total protein extracts and 
incubated at room temperature for 1 h. The luminescence 
of each sample was measured in a plate-reading 
luminometer Tristar LB941 (Berthold technologies).
Western blot analysis
Cells were lysed in RIPA buffer and protein 
concentration was determined as described above. 
Samples containing equal amounts of total protein extracts 
(depending on the antibody, 30–50 μg) in Laemmli buffer 
(62.5 mM Tris–HCl, pH 6.8, 2% SDS, 10% glycerol, 5% 
2-mercaptoethanol, 0.001% bromophenol blue) were 
separated by SDS-polyacrylamide gel electrophoresis, 
and transferred to PVDF Transfer membrane (Thermo 
scientific). The membranes were blocked in 3% BSA–
PBS-0.1% Tween at room temperature for 1 h and blots 
were probed overnight at 4°C with primary antibodies 
anti-phospho-Smad3 (Millipore, Temecula, CA, USA), 
anti-Smad3 (Millipore), anti-PARP (Cell signaling 
technology, Beverly, USA), anti-Caspase 3 (Cell Signaling 
Technology) or anti-β-actin (Sigma) antibodies. After 
incubation, the membranes were washed three times with 
washing buffer (PBS containing 0.1% Tween) for 5 min. 
Membranes were then incubated for 1 h with 1:10, 000 
diluted secondary antibodies (Santa Cruz Biotechnologies, 
Santa Cruz, CA) at room temperature. Specific proteins 
were detected using G-Box (Syngene, Cambridge, UK) 
after washing. Antibody binding was visualized with 
the enhanced chemiluminescence system (SuperSignal 
West Pico Chemiluminescent Substrate, ThermoSientific, 
Illkirch, France).
Micro-CT analysis
Analysis of bone microarchitecture was performed 
using the high-resolution X-ray micro-CT system 
for small-animal imaging SkyScan-1072 (SkyScan, 
Kartuizersweg, Belgium) at different tumor volumes 
(500, 1000 and 2500 mm3). All tibia/fibula were 
scanned using the same parameters (pixel size 18 
μm, 50 kV, 0.5-mm aluminium filter and 0.6 degrees 
per rotation step). Analysis of bone parameters were 
performed using the CTan software (Skyscan). The bone 
volume (BV) of ectopic bone was quantified over the 
total length of tibia bearing 2500 mm3 tumor. Trabecular 
structures positioned 0.2 mm below the growth plate 
were quantified over a length of 1 mm at 1000 mm3 
tumor volume since at higher tumor volume trabecular 
bone is completely destroyed by the tumor cells. 
Bone volume/trabecular volume (BV/TV), trabecular 
thickness (Tb.Th) and trabecular number (Tb.N) were 
determined.
Real-time polymerase chain reaction
Total RNA from cell lines was extracted using 
NucleoSpin®RNAII (Macherey Nagel, Duren, Germany). 
Total RNA from tumors was extracted using the TRIzol 
reagent (Invitrogen Life Technologies) after mechanical 
grinding with Turrax (IKA, Staufen, Switzerland). Total 
RNA was reversed transcribed using the Maxima H minus 
first stand cDNA synthesis kit (Thermoscientific). Real-
time monitoring of PCR amplification of complementary 
DNA was performed using DNA primers (primers 
sequences are available in Table 1) on CFX96 real-time 
PCR detector system (Bio-Rad, Marnes la Coquette, 
France) with SYBR PCR Master Mix buffer (Bio-Rad). 
Target gene expression was normalized to glyceraldehyde 
3-phosphatedehydrogenase (GAPDH) levels in respective 
samples as an internal standard.
Collagen degradation
The degradation of collagen was evaluated by the 
measure of pyridinoline excretion in mice serum using the 
MicroVue Serum PYD EIA kit (Quidel, CA).
Transient cell transfection, reporter assay and 
plasmid construct
Transient cell transfections were performed with 
jetPEI™ (Polyplus-transfection, Illkirch, France). The 
phRLMLP-Renilla luciferase expression vector was 
cotransfected in all experiments to monitor transfection 
efficiencies. Luciferase activity was determined with 
the Dual-Luciferase reporter assay system (Promega, 
Charbonnieres, France). The (CAGA)9-Luc construct was 
used as a reporter construct specific for Smad3/4-driven 
signaling.
Gelatin zymography
Cells were cultured without serum for 10 h and 
their conditioned media were analyzed by gelatin 
zymography in 10% polyacrylamide gels containing 
1 mg/ml gelatin (Sigma-Aldrich) as described 
previously [33].
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Statistical analysis
All analyses were performed using GraphPad Prism 
4.0 software (GraphPad Software, La Jolla, CA, USA) 
or Excel. Results of in vitro experiments were analyzed 
with the unpaired t-test and are given as means ± SD. 
For in vivo experiments, results from groups treated with 
1 μg/mouse/day or 5 μg/mouse/day were compared with 
no treated control groups using the unpaired t-test and 
are given as means ± SEM. Results with p < 0.05 were 
considered significant.
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